Immunotherapy of Lung Cancer in Countries with Limited Resources; Current Challenges and Potential Solutions

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2024 Aug 29

PMID 39205554

Authors

Arefeh Saeedian

Asghar Kazemzadeh

Seyed Alireza Javadinia

Affiliations

Soon will be listed here.

References

OBrien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L . Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022; 23(10):1274-1286. DOI: 10.1016/S1470-2045(22)00518-6. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Patel A, Goldstein D, Tannock I . Improving access to immunotherapy in low- and middle-income countries. Ann Oncol. 2022; 33(4):360-361. DOI: 10.1016/j.annonc.2022.01.003. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Punekar S, Shum E, Grello C, Lau S, Velcheti V . Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Front Oncol. 2022; 12:877594. PMC: 9382405. DOI: 10.3389/fonc.2022.877594. View

Unger J, Vaidya R, Hershman D, Minasian L, Fleury M . Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. J Natl Cancer Inst. 2019; 111(3):245-255. PMC: 6410951. DOI: 10.1093/jnci/djy221. View

Akl I, Berro J, Tfayli A, Shamseddine A, Mukherji D, Temraz S . Current Status and Future Perspectives of Immunotherapy in Middle-Income Countries: A Single-Center Early Experience. World J Oncol. 2020; 11(4):150-157. PMC: 7430853. DOI: 10.14740/wjon1277. View

Gettinger S, Rizvi N, Chow L, Borghaei H, Brahmer J, Ready N . Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016; 34(25):2980-7. PMC: 5569692. DOI: 10.1200/JCO.2016.66.9929. View

Lahiri A, Maji A, Potdar P, Singh N, Parikh P, Bisht B . Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023; 22(1):40. PMC: 9942077. DOI: 10.1186/s12943-023-01740-y. View

10.

Rajai N, Ghanbari A, Yoosefi M, Mohebi F, Mohajer B, Sheidaei A . National and subnational trends in incidence and mortality of lung cancer in Iran from 1990 to 2016. Asia Pac J Clin Oncol. 2020; 16(3):129-136. DOI: 10.1111/ajco.13303. View

11.

Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O . Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021; 398(10308):1344-1357. DOI: 10.1016/S0140-6736(21)02098-5. View

12.

Shokri Varniab Z, Tehrani Y, Pourabhari Langroudi A, Azadnajafabad S, Rezaei N, Rashidi M . Estimates of incidence, prevalence, mortality, and disability-adjusted life years of lung cancer in Iran, 1990-2019: A systematic analysis from the global burden of disease study 2019. Cancer Med. 2022; 11(23):4624-4640. PMC: 9741968. DOI: 10.1002/cam4.4792. View

13.

Morin S, Segafredo G, Piccolis M, Das A, Das M, Loffredi N . Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities. Lancet Glob Health. 2022; 11(1):e145-e154. DOI: 10.1016/S2214-109X(22)00460-0. View

14.

Osarogiagbon R, Sineshaw H, Unger J, Acuna-Villaorduna A, Goel S . Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes. Am Soc Clin Oncol Educ Book. 2021; 41:1-13. DOI: 10.1200/EDBK_323523. View